What Maculaser does

Maculaser Oy is a clinical-phase, privately held Finnish medical technology company (incorporated in Finland, headquartered in Espoo, Helsinki metropolitan area) developing a temperature-controlled retinal laser therapy platform for the treatment of retinal disorders. The platform is built on patented temperature-controlled retinal heating combined with electroretinography (ERG)-based thermal dosimetry, achieving approximately 0.6°C precision at the lesion threshold and enabling patient-specific, non-damaging exposure. The system uses a non-contact delivery lens, automated pupil tracking, and active over-heating detection, and operates on the principle that controlled local heating (around 44°C) activates the retina's natural defense mechanisms — including heat shock protein production, autophagy, and antioxidant stimulation — without structural damage. Targeted indications include age-related macular degeneration (AMD), diabetic macular edema (DME), and central serous chorioretinopathy (CSC), with the stated strategic intent of shifting treatment upstream from late-stage drug injections toward earlier, preventive intervention.

The technology originates from a 2013 research program at Aalto University, with the company itself founded in 2020. Maculaser holds five patent families with granted patents across the EU, US, and Japan (including JP 7475071 B2), and the core approach was validated in a 2025 peer-reviewed Nature Communications publication co-authored with Karolinska Institutet/St. Erik Eye Hospital and the University of Helsinki. The company is led by CEO and co-founder Jani Tirronen, CSO Teemu Turunen (PhD), CTO Jaakko Nieminen (PhD), and Head of Product Ossi Kaikkonen, supplemented by a Head of Regulatory Affairs/Quality Assurance and a Clinical Trial Manager hired in 2024.

Maculaser is pre-revenue and pre-commercial: its device is investigational use only, has not received FDA or CE clearance, and is not available for sale. The planned revenue model is hardware sales of the laser therapy system to ophthalmologists and eye care professionals, with a go-to-market approach centered on integrating an outpatient, repeatable procedure into regular eye-care workflows. Funding to date totals approximately €3M (public and private) as of 2023, with an additional undisclosed round co-led by ZEISS Ventures and M2Care announced in May 2026, plus non-dilutive support from Business Finland and the Instrumentarium Science Foundation, and participation in the €32M EU-funded PhotonMed initiative spanning 9 countries.

Name

Maculaser

Legal name

Maculaser Oy

Website

https://maculaser.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

1–10 employees

Short description

Maculaser is a Finnish clinical-phase medical technology company developing a temperature-controlled retinal laser therapy platform using ERG-based thermal dosimetry to deliver personalized, non-damaging treatments for retinal disorders including AMD, DME, and CSC, targeting ophthalmologists and eye care professionals.

Ownership category

akta.pro rank

Product category

Ophthalmic Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Vitreoretinal Surgical Devices (Vitrectomy Systems, Endolaser, Illumination, Tamponades) (HLAHAJAJ)

Keywords

• Retinal laser therapy
• Ophthalmic medical devices
• Temperature-controlled laser
• Retinal disorder treatment
• Electroretinography dosimetry

Headquarters

HQ city

Helsinki

HQ country

Finland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Medical Device Sales: Maculaser is developing a laser-based medical device for retinal treatment. As the technology progresses through clinical trials toward commercialization, the company plans to generate revenue through the sale of its temperature-controlled retinal laser therapy system to ophthalmologists and healthcare providers.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Maculaser is developing a temperature-controlled retinal laser therapy platform for the treatment of retinal disorders such as age-related macular degeneration (AMD), diabetic macular edema (DME), and central serous chorioretinopathy (CSC). The investigational medical device uses patented temperature-controlled retinal heating combined with electroretinography (ERG)-based thermal dosimetry to deliver personalized, non-damaging laser energy that activates the eye's natural cellular defense mechanisms. The platform integrates active retinal temperature monitoring, non-contact lens delivery, and automated pupil tracking, and is currently in clinical development for investigational use.

Product overview

Maculaser offers a single unified product: its Temperature-Controlled Retinal Laser Therapy Platform. This medical device system provides personalized, non-damaging retinal treatment through controlled heat exposure that activates natural cellular defense mechanisms (heat shock protein production, autophagy, and antioxidant stimulation). The platform consists of temperature monitoring and control algorithms, a non-contact lens delivery system, and automated pupil tracking. The technology targets conditions including age-related macular degeneration (AMD), diabetic macular edema (DME), and central serous chorioretinopathy (CSC), and is currently in clinical development with safety trials underway.

Differentiator

Problem solved

Functional benefit

Products and services

• Temperature-Controlled Retinal Laser Therapy Platform An investigational retinal laser therapy system for healthcare providers (ophthalmologists and eye-care professionals) that delivers personalized, non-damaging temperature-controlled retinal heating to trigger the eye's natural heat-shock, autophagy, and antioxidant defense mechanisms. The platform is being developed for the treatment of retinal disorders including age-related macular degeneration (AMD), diabetic macular edema (DME), and central serous chorioretinopathy (CSC). It is intended for investigational use only and is not yet approved or commercially available.

Quantifiable outcome

• Temperature-dosing precision of approximately 0.6°C at lesion threshold
• +3 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Four partnerships are on record, tiered flagship and core.

• PhotonMed InitiativeflagshipStrategic or Co-development Partner · 17 January 2025Maculaser is part of PhotonMed, a €32 million European Union (Chips Joint Undertaking, Chips JU)-funded initiative spanning 9 countries. This ambitious collaboration brings together leading research institutes and industrial partners to advance healthcare with cutting-edge photonics-based solutions. Maculaser is integrating innovative photonic technologies into their treatment platform to enhance outcomes for patients with macular degeneration and other retinal conditions.
• Aalto UniversitycoreStrategic or Co-development PartnerResearch collaboration with Aalto University researchers who have been pioneers in retinal temperature monitoring and heat shock response research since 2013. University provided foundational research for Maculaser's core technology.
• Karolinska Institutet / St. Erik Eye HospitalcoreStrategic or Co-development PartnerCollaborating researchers demonstrated that real-time electroretinography-based thermal dosimetry can activate cytoprotective pathways without retinal damage in preclinical pig model. Key partner in Nature Communications published research.
• University of HelsinkicoreStrategic or Co-development PartnerCollaborating institution in research demonstrating ERG-guided, temperature-controlled retinal laser study published in Nature Communications.

Scale indicators2 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Lumenis (Boston Scientific): Lumenis, now part of Boston Scientific, was a major ophthalmic laser company with strong retinal laser franchises. Its historical positioning as a retinal laser incumbent targeting the same AMD/DME treatment use cases makes it a useful comparable for category economics.
• Alcon: Alcon is a global ophthalmic incumbent with broad surgical and vision-care device franchises. Its constellation of retinal surgical and vitrectomy platforms is sold to the same retinal specialists targeted by Maculaser, and Alcon is a benchmark for the scale of a fully built-out ophthalmic commercial operation.
• Quantel Medical (Lumibird Medical): Quantel Medical (part of Lumibird) develops and markets ophthalmic laser systems including retinal photocoagulation lasers used by the same retinal specialists Maculaser targets. It is an incumbent in the retinal laser category with established global distribution.
• Topcon Healthcare: Topcon is a broad incumbent in ophthalmic equipment, with a portfolio of retinal imaging, diagnostics, and laser photocoagulation devices sold to retinal specialists globally. Its established retina-laser product line competes with the same retinal specialist customer segment Maculaser targets.
• Nidek: Nidek manufactures a broad portfolio of ophthalmic devices including retinal photocoagulation and pattern-scan laser systems sold to eye-care professionals. It is a comparable incumbent in retinal laser therapy with overlapping physician-customers and clinical use cases (DME, AMD).
• Carl Zeiss Meditec: Carl Zeiss Meditec is the broad ophthalmic incumbent whose corporate venture arm (ZEISS Ventures) just invested in Maculaser. The peer relationship is asymmetric — ZEISS is a potential strategic acquirer/distributor — but its ophthalmic laser, surgical, and diagnostic portfolio targets the same retinal specialists and disease indications.

Regional players

• Optos (Nikon Healthcare): Optos, part of Nikon Healthcare, sells ultra-widefield retinal imaging diagnostics widely used by retinal specialists — overlapping but complementary to Maculaser. It is a regional/adjacent peer serving the same specialist channel with diagnostic rather than therapeutic devices.

Direct peers

• Iridex Corporation: Iridex is a direct peer that markets ophthalmic laser systems including the PASCAL and MicroPulse platforms used for retinal laser therapy (including subthreshold and pattern scanning approaches for DME and AMD). They are the closest comparable to Maculaser in retinal laser thermal-therapy positioning and target physician base.

Others

• Genentech (Roche): Genentech/Roche markets Lucentis, a leading anti-VEGF injection for AMD and DME. As the incumbent drug therapy that Maculaser aims to treat upstream of, it is the most important indirect competitor and benchmarks the size of the market segment Maculaser hopes to divert into earlier laser intervention.
• Regeneron Pharmaceuticals: Regeneron markets Eylea, the leading anti-VEGF injection for AMD, DME, and diabetic retinopathy — the standard-of-care therapy that Maculaser's early-intervention positioning aims to displace. It is the dominant competitive alternative rather than a direct device peer, but its commercial scale benchmarks the opportunity.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Maculaser